On March 12, 2019 BioChain, a US-based company, reported that Epigenomics AG of Germany seriously violated the terms of an ongoing licensing contract by publicly announcing on March 6, 2019 the unilateral termination of BioChain’s licensing right of Septin9 marker in China (Press release, Biochain, MAR 13, 2019, View Source [SID1234534315]). The termination of the contract by Epigenomics is not legally effective.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioChain’s CEO, Grace Tian stated that according to the terms of the contract, disputes between the two parties require the parties to go through a mediation and arbitration process. BioChain filed a request with the contractually specified mediation and arbitration center on March 1, 2019 in accordance with the contract, before Epigenomics unilaterally terminated the contract.

BioChain and its affiliates, as the exclusive licensee of Septin9 marker in China, have diligently worked to expand its market position despite challenging market conditions, including the fact that one relevant patent of Epigenomics was invalidated in China and the news was publicly published in May 2018.

Tian said, "Epigenomics’ termination of the Septin9 contract has incurred damages to BioChain’s reputation and investment and BioChain will take further legal actions to protect its interests".